Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis

Addiction Science & Clinical Practice - 2021
Ximena A. Levander1, Kim Hoffman2, John W. McIlveen3, Dennis McCarty2, Javier Ponce Terashima4, P Todd Korthuis2
1Division of General Internal Medicine & Geriatrics, Department of Medicine, Addiction Medicine Section, Oregon Health & Science University, 3181 SW Sam Jackson Park Road Mail Code – L475, Portland, OR, 97239-3098, USA
2Oregon Health & Science University-Portland State University School of Public Health, Portland, OR, USA
3Oregon Health Authority State Opioid Treatment Authority, Salem, OR, USA
4Department of Psychiatry,Yale University, New Haven, CT, USA

Tóm tắt

Abstract Background In the United States, methadone for opioid use disorder (OUD) is highly regulated. Federal agencies announced guidelines in March 2020 allowing for relaxation of take-home methadone dispensing at opioid treatment programs (OTPs) to improve treatment access and reduce COVID-19 transmission risk during the public health emergency. We explored patient perspectives at three OTPs serving rural communities on how take-home policy changes were received and implemented and how these changes impacted their addiction treatment and recovery. Methods We completed semi-structured individual qualitative interviews in 2 phases: (1) August–October 2020 and (2) November 2020–January 2021 (total n = 46), anticipating possible policy changes as the pandemic progressed. We interviewed patients with OUD enrolled at 3 rural OTPs in Oregon. Participants received varying take-home methadone allowances following the COVID-19-related policy changes. All interviews were conducted via phone, audio-recorded, and transcribed. We conducted a thematic analysis, iteratively coding transcripts, and deductively and inductively generating codes. Results The 46 participants included 50% women and 89% had Medicaid insurance. Three main themes emerged in the analysis, with no differences between study phases: (1) Adapting to changing OTP policies throughout the pandemic; (2) Recognizing the benefits, and occasional struggles, with increased take-home methadone dosing; and (3) Continuing policies and procedures post-pandemic. Participants described fears and anxieties around ongoing methadone access and safety concerns prior to OTP policy changes, but quickly adapted as protocols soon seemed “natural.” The majority of participants acknowledged significant benefits to increased take-homes independent of reducing COVID-19 infection risk including feeling “more like a normal person,” improved recovery support, reduced time traveling, and having more time with family and for work. Looking to a post-pandemic future, participants thought some COVID-19-related safety protocols should continue that would reduce risk of other infections, make OTP settings less stressful, and result in more individualized care. Conclusions As the pandemic progressed, study participants adapted to rapidly changing OTP policies. Participants noted many unanticipated benefits to increased take-home methadone and other COVID-19 protocols including strengthened self-efficacy and recovery and reduced interpersonal conflict, with limited evidence of diversion. Patient perspectives should inform future policies to better address the ongoing overdose epidemic.

Từ khóa


Tài liệu tham khảo

National Academies of Sciences Engineering and Medicine. Medications for Opioid Use Disorder Save Lives. Washington: The National Academies Press; 2019. doi:https://doi.org/10.17226/25310

Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services (N-SSATS): 2019. Rockville, MD; 2020. https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services.

Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment. Federal Regulation of Methadone Treatment. Vol 5. (Rettig RA, Yarmolinsky A, eds.). Washington, DC: National Academies Press; 1995. doi:https://doi.org/10.1001/jama.1995.03530160059035

Substance Abuse and Mental Health Services Administration (SAMHSA). Federal Guidelines for Opioid Treatment Programs. Rockville, MD; 2015. http://store.samhsa.gov.

Jackson JR, Harle CA, Silverman RD, Simon K, Menachemi N. Characterizing variability in state-level regulations governing opioid treatment programs. J Subst Abuse Treat. 2020;115: 108008. https://doi.org/10.1016/j.jsat.2020.108008.

Peles E, Schreibe S, Sason A, Adelson M. Earning, “Take-Home” privileges and long-term outcome in a methadone maintenance treatment program. J Addict Med. 2011;5(2):92–8. https://doi.org/10.1097/ADM.0b013e3181e6ad48.

Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19. J Subst Abuse Treat. 2020. https://doi.org/10.1016/j.jsat.2020.108219.

Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4(4):204–10. https://doi.org/10.1097/ADM.0b013e3181cc9610.

Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8. https://doi.org/10.1016/j.drugalcdep.2015.12.031.

Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019. https://doi.org/10.1001/jamanetworkopen.2019.6373.

Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273–88. https://doi.org/10.1080/00952990.2019.1694536.

Levander XA, Wakeman SE. Covid-19 Will Worsen the Opioid Crisis If We Don’t Prepare Now. Stat News - First Opinion. https://www.statnews.com/2020/03/17/covid-19-will-worsen-the-opioid-overdose-crisis-if-we-dont-prepare-now/comment-page-1/. Published March 2020. Accessed May 24, 2021.

Insinger A. Methadone clinic lines and packed waiting rooms leave clients vulnerable to the coronavirus. Stat News - Health. https://www.statnews.com/2020/04/09/methadone-clinics-leave-clients-vulnerable-to-coronavirus/. Published April 9, 2020. Accessed June 14, 2021.

Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1212.

Khatri UG, Perrone J. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 2020;14(4):6–7. https://doi.org/10.1097/ADM.0000000000000684.

Becker WC, Fiellin DA. When epidemics collide: Coronavirus Disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1210.

Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57–8. https://doi.org/10.7326/M20-1141.

Ahmad F, Rossen L, Sutton P. Provisional Drug Overdose Death Counts. National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Published November 2020. Accessed 2 Dec 2020.

Substance Abuse and Mental Health Services Administration. Opioid Treatment Program (OTP) Guidance. Rockville, MD; 2020. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf. Accessed 13 Nov 2020.

McIlveen JW, Hoffman K, Priest KC, Choi D, Korthuis PT, McCarty D. Reduction in Oregon’s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication. J Addict Med. 2021. https://doi.org/10.1097/ADM.0000000000000812 (Epub ahead of print).

Dunlop A, Lokuge B, Masters D, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26. https://doi.org/10.1186/s12954-020-00370-7.

Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing—the need for prevention and early intervention. JAMA Intern Med. 2020;180(6):817–8. https://doi.org/10.1001/jamainternmed.2020.1562.

Stack E, Leichtling G, Larsen JE, et al. The impacts of COVID-19 on mental health substance use, and overdose concerns of people who use drugs in rural communities. J Addict Med. 2020. https://doi.org/10.1097/ADM.0000000000000770.

Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Heal Care. 2007;19(6):349–57. https://doi.org/10.1093/intqhc/mzm042.

Braun V, Clarke V. Qualitative research in psychology using thematic analysis in psychology using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.

Green J, Thorogood N. Qualitative methods for health research. 2004. https://doi.org/10.5860/choice.47-0901

Morse JM. Critical analysis of strategies for determining rigor in qualitative inquiry. Qual Health Res. 2015;25(9):1212–22. https://doi.org/10.1177/1049732315588501.

Levander XA, Pytell JD, Stoller KB, Korthuis PT. COVID-19-related policy changes for methadone take-home dosing: a multistate survey of opioid treatment program leadership. Subst Abus. 2021. https://doi.org/10.1080/08897077.2021.1986768.

Marchand K, Beaumont S, Westfall J, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abus Treat Prev Policy. 2019;14(1):1–15. https://doi.org/10.1186/s13011-019-0227-0.

Bao Y, Williams AR, Schackman BR. COVID-19 could change the way we respond to the opioid crisis-for the better. Psychiatr Serv. 2020;71(12):1214–5. https://doi.org/10.1176/appi.ps.202000226.

Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–9. https://doi.org/10.1080/08897077.2020.1752351.

Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214(June): 108176. https://doi.org/10.1016/j.drugalcdep.2020.108176.

Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiatry. 2020. https://doi.org/10.1001/jamapsychiatry.2020.4218.

Trujols J, Larrabeiti A, Sànchez O, Madrid M, De Andrés S, Duran-Sindreu S. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? J Subst Abuse Treat. 2020;119(June): 108154. https://doi.org/10.1016/j.jsat.2020.108154.

Frank D. A chance to do it better: methadone maintenance treatment in the age of Covid-19. J Subst Abuse Treat. 2020;2021(123): 108246. https://doi.org/10.1016/j.jsat.2020.108246.

Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257–65. https://doi.org/10.1016/j.drugpo.2019.01.020.

Calcaterra SL, Bach P, Chadi A, et al. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–42. https://doi.org/10.1007/s11606-018-4801-3.

Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder—decades of effectiveness but still miles away in the US. JAMA Psychiatry. 2020. https://doi.org/10.2307/j.ctvk12rb0.

Cochran G, Bruneau J, Cox N, Gordon AJ. Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic. Subst Abus. 2020;41(3):269–74. https://doi.org/10.1080/08897077.2020.1787300.

Johnson Q, Mund B, Joudrey PJ. Improving rural access to opioid treatment programs. J Law, Med Ethics. 2018;46(2):437–9. https://doi.org/10.1177/1073110518782951.

Joudrey PJ, Chadi N, Roy P, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alcohol Depend. 2020. https://doi.org/10.1016/j.drugalcdep.2020.107968.

Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: provider perspectives. J Subst Abuse Treat. 2020;2021(124): 108223. https://doi.org/10.1016/j.jsat.2020.108223.

United States Government Accountability Office. Methadone-associated overdose deaths: factors contributing to increased deaths and efforts to prevent them. Rockville, MD; 2009.

Hunter SB, Dopp AR, Ober AJ, Uscher-Pines L. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2020;2021(124): 108288. https://doi.org/10.1016/j.jsat.2021.108288.

Dunn KE, Brooner RK, Stoller KB. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. J Subst Abuse Treat. 2021. https://doi.org/10.1016/j.jsat.2020.108197.

Kidorf M, Brooner RK, Dunn KE, Peirce JM. Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic. J Subst Abuse Treat. 2021. https://doi.org/10.1016/j.jsat.2021.108328.

Chan B, Hoffman KA, Bougatsos C, Grusing S, Chou R, McCarty D. Mobile methadone medication units: a brief history, scoping review and research opportunity. J Subst Abuse Treat. 2021;129(January): 108483. https://doi.org/10.1016/j.jsat.2021.108483.

Department of Justice Drug Enforcement Administration. Registration requirements for narcotic treatment programs with mobile components. Vol 86. United States; 2021:33861–33875. https://doi.org/10.1016/0196-335x(80)90058-8

Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63(3):200–5.

Samet JH, Botticelli M, Bharel M. Methadone in primary care—one small step for congress, one giant leap for addiction treatment. N Engl J Med. 2018;379(1):7–8. https://doi.org/10.1056/NEJMp1803982.

Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care. JAMA. 2001;286(14):1724. https://doi.org/10.1001/jama.286.14.1724.

Neale J, Miller P, West R. Reporting quantitative information in qualitative research: guidance for authors and reviewers. Addiction. 2014;109(2):175–6. https://doi.org/10.1111/add.12408.

Brothers S, Viera A, Heimer R. Changes in methadone clinic practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131: 108449. https://doi.org/10.1016/j.jsat.2021.108449.

Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123: 108276. https://doi.org/10.1016/j.jsat.2021.108276.

Lippold K, Ali B. Racial/ethnic differences in opioid-involved overdose deaths across metropolitan and non-metropolitan areas in the United States, 1999–2017. Drug Alcohol Depend. 2020;212: 108059. https://doi.org/10.1016/j.drugalcdep.2020.108059.

James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404–21. https://doi.org/10.1177/1073110518782949.

Peterkin A, Davis CS, Weinstein Z. Permanent methadone treatment reform needed to combat the opioid crisis and structural racism. J Addict Med. 2021. https://doi.org/10.1097/adm.0000000000000841.

Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21. https://doi.org/10.1016/j.drugalcdep.2016.03.028.

Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Heal Serv Res. 2013;40(3):367–77. https://doi.org/10.1007/s11414-013-9341-3.

Goedel WC, Shapiro A, Cerdá M, Tsai JW, Hadland SE, Marshall BDL. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020. https://doi.org/10.1001/jamanetworkopen.2020.3711.

Thông tin
Thông tin xuất bản

Addiction Science & Clinical Practice

Thông tin tác giả